The use of ondansetron in patients receiving multiple-day cisplatin regimens.
The control of nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy has remained difficult, even with the use of combination antiemetic regimens containing metoclopramide. Although these patients receive a lower daily dose of cisplatin, the emetogenic potential remains high. In addition, many of the patients receiving multiple-day cisplatin regimens are young (eg, testicular cancer patients) and, therefore, have particular problems with the extrapyramidal side effects associated with metoclopramide. Studies show that ondansetron, used as a single antiemetic agent, is effective, safe, and well tolerated in the control of nausea and vomiting in patients receiving multiple-day cisplatin regimens.
Hainsworth
J D
JD
Vanderbilt University, Nashville, TN.
D000328:Adult; D000932:Antiemetics / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D017294:Ondansetron; D012702:Serotonin Antagonists / Q000627:therapeutic use*
D000932:Antiemetics; D007093:Imidazoles; D012702:Serotonin Antagonists; D017294:Ondansetron; D002945:Cisplatin